Approval · Notice of Compliance 16114 · 2014
MINT-DUTASTERIDE: Notice of Compliance 16114
Issued September 17, 2014
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 16114
- Date
- September 17, 2014
- Company
- Mint Pharmaceuticals IncMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Admin
- Reason
- Licensing agreement between two companies
- Therapeutic class
- Type i and ii alpha-reductase inhibitor
- Canadian reference product
- AVODART (Glaxosmithkline Inc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| MINT-DUTASTERIDE | 02428873 | Marketed |
Medicinal ingredients
- DUTASTERIDE 0.5 MG per CAP